Published in Cancer Weekly, November 16th, 2004
"Glioblastoma multiforme (GBM) remains the most devastating primary tumor in neuro-oncology," researchers in France explained. "Targeting of the human epithelial receptor type 2 (HER2)-neu receptor by specific antibodies is a recent well-established therapy for breast tumors."
"Human epithelial receptor type 2/neu is a transmembrane tyrosine/kinase receptor that appears to be important for the regulation of cancer growth," noted J.F. Mineo and colleagues at Roger Salengro Hospital in Lille. "Human epithelial receptor type 2/neu is not expressed...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.